WO2011026351 A CYANOVIRIN N MUTANT, MODIFIED DERIVATIVE AND USES THEREOF

Settings

Stemming

Single Family Member

Feedback

Goto Application

Publication Number WO/2011/026351

Publication Date 10.03.2011

International Application No. PCT/CN2010/073124

International Filing Date 24.05.2010

IPC

C07K 14/405 2006.01

C12N 15/31 2006.01

C12N 15/63 2006.01

C12N 1/21 2006.01

C07K 17/08 2006.01

A61K 38/16 2006.01

View more classifications

C07K 14/405 2006.01

C12N 15/31 2006.01

C12N 15/63 2006.01

C12N 1/21 2006.01

C07K 17/08 2006.01

A61K 38/16 2006.01

A61K 47/48 2006.01

A61P 31/18 2006.01

C12R 1/89 2006.01

C12R 1/19 2006.01

View less classifications

CPC

A61K 38/00

A61K 47/60

A61P 31/18

C07K 14/195

Applicants

暨南大学 JINAN UNIVERSITY [CN]/[CN] (AllExceptUS)
熊盛 XIONG, Sheng [CN]/[CN] (UsOnly)
陈伟 CHEN, Wei [CN]/[CN] (UsOnly)
钱垂文 QIAN, Chuiwen [CN]/[CN] (UsOnly)
王一飞 WANG, Yifei [CN]/[CN] (UsOnly)
北里·海雄 KITAZATO, Kaio [CN]/[CN] (UsOnly)

Inventors

熊盛 XIONG, Sheng
陈伟 CHEN, Wei
钱垂文 QIAN, Chuiwen
王一飞 WANG, Yifei
北里·海雄 KITAZATO, Kaio

Agents

广州市华学知识产权代理有限公司 GUANGZHOU HUAXUE INTELLECTUAL PROPERTY AGENCY CO., LTD.

Priority Data

200910192063.0

04.09.2009

Publication Language Chinese (ZH)

Filing Language Chinese (ZH)

Designated States

View all

Title

(EN) A CYANOVIRIN N MUTANT, MODIFIED DERIVATIVE AND USES THEREOF

(FR) MUTANT DE CYANOVIRINE N, DÉRIVÉ MODIFIÉ CORRESPONDANT ET UTILISATIONS ASSOCIÉES

(ZH) 一种蓝藻病毒蛋白N 突变体、其修饰衍生物及应用

Abstract

(EN)

A cyanovirin N (CVN) mutant, its PEG modified derivative and their uses in preparing drugs. The said cyanovirin N mutant is composed of sequence A and sequence B: sequence A is a linker peptide with hydrophilicity and flexibility, sequence B is a codon optimized sequence of cyanovirin N. The cyanoviein N mutant is modified by PEG to obtain derivative. The mutant and the derivative both exhibit good anti-HIV activities, and have prospect of being used in preparing drugs for anti-HIV and other viral microorganism.

(FR)

La présente invention concerne un mutant de cyanovirine N (CVN), son dérivé modifié par du PEG et leurs utilisations pour la préparation de médicaments. Ledit mutant de cyanovirine N se compose de la séquence A et de la séquence B : la séquence A est un peptide lieur hydrophile et flexible, la séquence B est une séquence à codons optimisés de la cyanovirine N. Le mutant de cyanovirine N est modifié par du PEG pour obtenir un dérivé. Le mutant et le dérivé présentent tous deux de bonnes activités anti-VIH, et sont destinés à être utilisés pour la préparation de médicaments contre le VIH et d'autres microorganismes viraux.

Also published as

CN200910192063.0

IN2837/DELNP/2012

JP2013503609

Latest bibliographic data on file with the International Bureau

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
14	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
405	from algae

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology
11	DNA or RNA fragments; Modified forms thereof
31	Genes encoding microbial proteins, e.g. enterotoxins

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology
63	Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1	Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20	Bacteria; Culture media therefor
21	modified by introduction of foreign genetic material

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
17	Carrier-bound or immobilised peptides; Preparation thereof
02	Peptides being immobilised on, or in, an organic carrier
08	the carrier being a synthetic polymer

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. WO2011026351 - A CYANOVIRIN N MUTANT, MODIFIED DERIVATIVE AND USES THEREOF

WIPO Translate

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38	Medicinal preparations containing peptides
16	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31	Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12	Antivirals
14	for RNA viruses
18	for HIV

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
R	INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C-C12Q75
1	Microorganisms
89	Algae

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
56	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60	the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
56	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60	the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol